Purpose:To assess quantitative susceptibility mapping (QSM) in the depiction of the subthalamic nucleus (STN) by using 3-T magnetic resonance (MR) imaging. Materials and Methods:This study was HIPAA compliant and institutional review board approved. Ten healthy subjects (five men, five women; mean age, 24 years 6 3 [standard deviation]; age range, 21-33 years) and eight patients with Parkinson disease (five men, three women; mean age, 57 years 6 14; age range, 25-69 years) who were referred by neurologists for preoperative navigation MR imaging prior to deep brain stimulator placement were included in this study. T2-weighted (T2w), T2*-weighted (T2*w), R2* mapping (R2*), phase, susceptibility-weighted (SW), and QSM images were reconstructed for STN depiction. Qualitative visualization scores of STN and internal globus pallidus (GPi) were recorded by two neuroradiologists on all images. Contrast-to-noise ratios (CNRs) of the STN and GPi were also measured. Measurement differences were assessed by using the Wilcoxon rank sum test and the signed rank test. Results:Qualitative scores were significantly higher on QSM images than on T2w, T2*w, R2*, phase, or SW images (P , .05) for STN and GPi visualization. Median CNR was 6.4 and 10.7 times higher on QSM images than on T2w images for differentiation of STN from the zona incerta and substantia nigra, respectively, and was 22.7 and 9.1 times higher on QSM images than on T2w images for differentiation of GPi from the internal capsule and external globus pallidus, respectively. CNR differences between QSM images and all other images were significant (P , .01). Conclusion:QSM at 3-T MR imaging performs significantly better than current standard-of-care sequences in the depiction of the STN.q RSNA, 2013Supplemental material: http://radiology.rsna.org/lookup /suppl
Purpose To assess the reproducibility of brain quantitative susceptibility mapping (QSM) in healthy subjects and in patients with multiple sclerosis (MS) on 1.5 and 3T scanners from two vendors. Materials and Methods Ten healthy volunteers and 10 patients were scanned twice on a 3T scanner from one vendor. The healthy volunteers were also scanned on a 1.5T scanner from the same vendor and on a 3T scanner from a second vendor. Similar imaging parameters were used for all scans. QSM images were reconstructed using a recently developed nonlinear morphology-enabled dipole inversion (MEDI) algorithm with L1 regularization. Region-of-interest (ROI) measurements were obtained for 20 major brain structures. Reproducibility was evaluated with voxel-wise and ROI-based Bland–Altman plots and linear correlation analysis. Results ROI-based QSM measurements showed excellent correlation between all repeated scans (correlation coefficient R ≥ 0.97), with a mean difference of less than 1.24 ppb (healthy subjects) and 4.15 ppb (patients), and 95% limits of agreements of within −25.5 to 25.0 ppb (healthy subjects) and −35.8 to 27.6 ppb (patients). Voxel-based QSM measurements had a good correlation (0.64 ≤ R ≤ 0.88) and limits of agreements of −60 to 60 ppb or less. Conclusion Brain QSM measurements have good interscanner and same-scanner reproducibility for healthy and MS subjects, respectively, on the systems evaluated in this study.
Quantitative susceptibility mapping (QSM) is an MR technique that depicts and quantifies magnetic susceptibility sources. Mapping iron, the dominant susceptibility source in the brain, has many important clinical applications. Herein, we review QSM applications in the diagnosis, medical management, and surgical treatment of disease. To assist in early disease diagnosis, QSM can identify elevated iron levels in the motor cortex of amyotrophic lateral sclerosis patients, in the substantia nigra of Parkinson's disease (PD) patients, in the globus pallidus, putamen, and caudate of Huntington's disease patients, and in the basal ganglia of Wilson's disease patients. Additionally, QSM can distinguish between hemorrhage and calcification, which could prove useful in tumor subclassification, and can measure microbleeds in traumatic brain injury patients. In guiding medical management, QSM can be used to monitor iron chelation therapy in PD patients, to monitor smoldering inflammation of multiple sclerosis (MS) lesions after the blood-brain barrier (BBB) seals, to monitor active inflammation of MS lesions before the BBB seals without using gadolinium, and to monitor hematoma volume in intracerebral hemorrhage. QSM can also guide neurosurgical treatment. Neurosurgeons require accurate depiction of the subthalamic nucleus, a tiny deep gray matter nucleus, prior to inserting deep brain stimulation electrodes into the brains of PD patients. QSM is arguably the best imaging tool for depiction of the subthalamic nucleus. Finally, we discuss future directions, including bone QSM, cardiac QSM, and using QSM to map cerebral metabolic rate of oxygen. Copyright © 2016 John Wiley & Sons, Ltd.
Purpose To demonstrate the phase and QSM patterns created by solid and shell spatial distributions of magnetic susceptibility in MS lesions. Materials and Methods Numerical simulations and experimental phantoms of solid- and shell-shaped magnetic susceptibility sources were used to generate magnitude, phase, and QSM images. Imaging of 20 consecutive MS patients was also reviewed for this IRB-approved MRI study to identify appearance of solid and shell lesions on phase and QSM images. Results Solid and shell susceptibility sources were correctly reconstructed in QSM images, while the corresponding phase images depicted both geometries with shell-like patterns, making the underlying susceptibility distribution difficult to determine using phase alone. In MS patients, of the 60 largest lesions identified on T2, 30 lesions were detected on both QSM and phase, of which 83% were solid and 17% were shells on QSM, and of which 30% were solid and 70% were shell on phase. Of the 21 shell-like lesions on phase, 76% appeared solid on QSM, 24% appeared shell on QSM. Of the five shell-like lesions on QSM, all were shell-like on phase. Conclusion QSM accurately depicts both solid and shell patterns of magnetic susceptibility, while phase imaging fails to distinguish them.
In patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy (NAC), some patients achieve a complete pathologic response (pCR), some achieve a partial response, and some do not respond at all or even progress. Accurate prediction of treatment response has the potential to improve patient care by improving prognostication, enabling de-escalation of toxic treatment that has little benefit, facilitating upfront use of novel targeted therapies, and avoiding delays to surgery. Visual inspection of a patient’s tumor on multiparametric MRI is insufficient to predict that patient’s response to NAC. However, machine learning and deep learning approaches using a mix of qualitative and quantitative MRI features have recently been applied to predict treatment response early in the course of or even before the start of NAC. This is a novel field but the data published so far has shown promising results. We provide an overview of the machine learning and deep learning models developed to date, as well as discuss some of the challenges to clinical implementation.
BackgroundCancer patients often have a history of chemotherapy, putting them at increased risk of liver toxicity and pancytopenia, leading to elevated liver fat and elevated liver iron respectively. T1-in-and-out-of-phase, the conventional MR technique for liver fat assessment, fails to detect elevated liver fat in the presence of concomitantly elevated liver iron. IDEAL-IQ is a more recently introduced MR fat quantification method that corrects for multiple confounding factors, including elevated liver iron.MethodsThis retrospective study was approved by the institutional review board with a waiver for informed consent. We reviewed the MRI studies of 50 cancer patients (30 males, 20 females, 50–78 years old) whose exams included (1) T1-in-and-out-of-phase, (2) IDEAL-IQ, and (3) T2* mapping. Two readers independently assessed fat and iron content from conventional and IDEAL-IQ MR methods. Intraclass correlation coefficient (ICC) was estimated to evaluate agreement between conventional MRI and IDEAL-IQ in measuring R2* level (a surrogate for iron level), and in measuring fat level. Agreement between the two readers was also assessed. Wilcoxon signed rank test was employed to compare iron level and fat fraction between conventional MRI and IDEAL-IQ.ResultsTwenty percent of patients had both elevated liver iron and moderate/severe hepatic steatosis. Across all patients, there was high agreement between readers for IDEAL-IQ fat fraction (ICC = 0.957) and IDEAL R2* (ICC = 0.971) measurements, but lower agreement for conventional fat fraction measurements (ICC = 0.626). The fat fractions calculated with IOP were statistically significantly different from those calculated with IDEAL-IQ (reader 1: p < 0.001, reader 2: p < 0.001).ConclusionFat measurements using IDEAL-IQ and IOP diverged in patients with concomitantly elevated liver fat and liver iron. Given prior work validating IDEAL-IQ, these diverging measurements indicate that IOP is inadequate to screen for hepatic steatosis in our cancer population.
This article will undergo copyediting, layout, and proof review before it is published in its final version. Please note that during production of the final copyedited article, errors may be discovered which could affect the content.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.